Healthcare and biotech remain among the most capital-intensive, expertise-driven corners of venture investing. Backing a therapeutics or medtech company requires more than a checkbook — it requires investors who understand clinical trial design, regulatory pathways, reimbursement dynamics, and the long time horizons that define life sciences. Below is a look at nine US venture firms that continue to actively back healthcare and biotech founders, from first-in-human therapeutics to digital health platforms.
OrbiMed
Founded in 1998 by Samuel Isaly, Michael Sheffery, and Arvind Desai, OrbiMed is a premier global healthcare investment firm headquartered in New York City with a presence in major hubs like Boston, Shanghai, and Herzliya [2]. Managing approximately $21 billion in assets, the firm is distinguished by its singular focus on the healthcare sector, covering everything from early-stage biopharmaceuticals to medical devices, diagnostics, and healthcare services [4]. OrbiMed’s team consists of over 150 professionals who blend medical, scientific, and financial expertise to identify and support transformative innovations [4]. The firm is known for its multi-stage flexibility, leading seed-stage venture rounds and participating in large crossover financings and royalty deals [1]. Notable portfolio companies include Intellia Therapeutics, a leader in CRISPR genome editing, where OrbiMed served as a foundational investor and provided critical structured debt to support the path to commercialization [5]. The firm also backed argenx, which successfully developed therapies for severe autoimmune diseases and achieved one of the most significant biotech IPOs of the decade [5]. By providing both capital and deep operational insights, OrbiMed helps entrepreneurs navigate the high-risk regulatory and clinical pathways required to bring life-saving therapies to global markets [1][4].
New Enterprise Associates (NEA)
Established in 1977 by venture pioneers Dick Kramlich, Chuck Newhall, and Frank Bonsal, New Enterprise Associates (NEA) is one of the world's most enduring and largest venture capital firms [2]. Headquartered in Menlo Park, California, NEA manages over $25 billion in committed capital across a diversified strategy that encompasses technology and healthcare [2]. The firm’s healthcare practice is a global leader, investing in biopharma, medtech, and healthcare services from inception through every growth milestone [1][3]. NEA distinguishes itself through its 'company-builder' mindset, providing founders with a massive network and operational resources to scale businesses from a simple idea to an industry-leading IPO [1]. A key portfolio example is Adaptive Biotechnologies, where NEA led early rounds to support the development of high-throughput sequencing of the adaptive immune system [5]. Another notable success is Celator Pharmaceuticals, a biotech specializing in oncology that NEA supported through clinical development until its successful acquisition by Jazz Pharmaceuticals [5]. With nearly five decades of experience, NEA remains a cornerstone of the venture ecosystem, known for its stability and the ability to partner with founders across multiple generations of innovation [1][2].
Versant Ventures
Founded in 1999, Versant Ventures is a San Francisco-based healthcare investment firm that manages $5.5 billion in capital [1][2]. The firm is widely recognized for its high-conviction, company-creation model, utilizing its proprietary 'Discovery Engines'—in-house laboratories like Ridgeline in Basel and Inception in San Diego—to launch new biotechnology companies based on groundbreaking academic research [1][5]. This model allows Versant to staff new ventures with multidisciplinary scientists and provide the necessary wet-lab infrastructure to de-risk science before significant external capital is raised [5]. Since its founding, Versant has seen more than 50 portfolio companies reach an IPO and another 50 achieve successful M&A outcomes [1]. Notable portfolio companies include Chinook Therapeutics, which Versant incubated to develop precision medicines for kidney diseases before its 2020 IPO and subsequent $3.2 billion acquisition by Novartis [2][5]. The firm also launched Monte Rosa Therapeutics, a leader in protein degradation therapies that reached the public markets in 2021 [2]. Versant’s focus on long-term clinical outcomes and its unique operational infrastructure distinguish it as a premier partner for founders translating complex biology into next-generation therapeutics [5].
ARCH Venture Partners
ARCH Venture Partners, established in 1986 by Steven Lazarus, Keith Crandell, Robert Nelsen, and Clinton Bybee, is a Chicago-based firm that manages approximately $12 billion in assets [4][5]. Originating from a technology transfer partnership between the University of Chicago and Argonne National Laboratory, ARCH has become one of biotech's most influential and contrarian investors [5]. The firm is distinguished by its 'science-first' approach, often making massive, early-stage bets on revolutionary technologies that address the root causes of disease [2][5]. ARCH partners are deeply involved in company formation, frequently serving as interim executives and seeding companies directly out of research institutions [5]. Notable portfolio companies include Juno Therapeutics, a pioneer in CAR-T cell therapy for which ARCH provided foundational funding before its multi-billion-dollar acquisition by Celgene [5]. The firm also backed Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) medicines, supporting the company from its early development through commercial success [1]. ARCH’s ability to anticipate and fund major technical 'waves' years before they become mainstream has made it a partner of choice for founders tackling the most difficult challenges in modern medicine [3][5].
Flagship Pioneering
Flagship Pioneering, founded in 2000 by Noubar Afeyan and Ed Kania, is a Cambridge-based institution that has transformed the biotechnology sector through its systematic company-creation model [3][4]. Unlike traditional venture capital firms, Flagship does not primarily invest in outside pitches; instead, it uses its 'Flagship Labs' unit to originate new ventures internally [1][2]. This process begins with 'what if' questions that lead to scientific explorations, prototype companies (ProtoCos), and eventually fully funded commercial entities [2]. Over its history, the firm has originated more than 120 companies and generated over $30 billion in aggregate value [4]. Flagship's most prominent success is Moderna, which it launched in 2010 to develop messenger RNA (mRNA) technology, eventually resulting in a transformative COVID-19 vaccine and a multi-billion-dollar public valuation [3][5]. Other notable companies created by Flagship include Denali Therapeutics, focused on neurodegenerative diseases, and Indigo Agriculture, which uses the microbiome to improve crop health [3][5]. By acting as the principal founder, funder, and owner, Flagship ensures its ventures have the institutional resources and strategic continuity required to pioneer entire new categories of medicine and sustainability [1][2].
Atlas Venture
Founded in 1980 by Michiel de Haan, Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and investing in early-stage biotechnology companies [1][5]. Managing over $2.7 billion in assets, Atlas shifted in 2014 to a pure-play biotech model, focusing on translating high-impact science into new medicines [1]. The firm is distinguished by its seed-led venture creation strategy, where it works closely with entrepreneurs-in-residence and founding scientists to shape platform and product companies within its in-house incubator [5]. Atlas emphasizes a patient-centric, science-first culture and provides the operational support and capital needed for companies to reach clinical and commercial milestones [5]. Notable portfolio companies include Scholar Rock, which Atlas helped build from a seed-stage platform to a public leader in muscle and tissue biology [3]. The firm also backed Intellia Therapeutics and Kymera Therapeutics, demonstrating its ability to nurture companies at the forefront of gene editing and protein degradation [5]. By maintaining a single-office focus in the heart of the Cambridge biotech hub, Atlas provides its portfolio companies with unparalleled access to top-tier academic and industrial networks [1][5].
Sofinnova Investments
Sofinnova Investments, established in 1976 by Jean Deléage and Alain Azan, is a Menlo Park-based healthcare investment firm that manages approximately $4.4 billion in assets [1][2]. With a legacy that includes an early investment in Genentech, the firm focuses on biopharmaceutical and medtech companies, primarily targeting late-preclinical and clinical-stage therapeutics [1][2]. Sofinnova is distinguished by its long-term investment approach and its capability to guide entrepreneurs through the complex regulatory and clinical milestones required for success [1][5]. The firm operates as an independent U.S. entity, separate from its Paris-based namesake, and leverages its team's deep operational and medical experience to build market-leading healthcare businesses [2][5]. Notable portfolio companies include Relypsa, a cardiovascular drug developer that Sofinnova supported through its development and eventual acquisition by Galenica [1]. The firm also backed Cerevel Therapeutics, a neuroscience-focused clinical-stage company that later achieved a successful public market debut [1]. By providing both financial capital and strategic board-level guidance, Sofinnova helps life sciences founders de-risk their programs and achieve significant clinical and commercial outcomes [1][5].
Polaris Partners
Founded in 1996 by Jon Flint, Terry McGuire, and Steve Arnold, Polaris Partners is a Boston-based venture capital firm that manages over $5 billion in assets [1]. The firm invests across the healthcare and technology sectors, with a healthcare practice that is particularly well-known for its role in founding and seeding companies at their inception [1][5]. Polaris distinguishes itself by using a 'founder-in-residence' model, partnering with top scientific talent to build new therapeutics companies around emerging biology and breakthrough technology [1][2]. The firm provides hands-on operational support and strategic coaching to help first-time and repeat entrepreneurs navigate the challenges of company building [2]. Notable portfolio companies include Editas Medicine, a leader in CRISPR gene editing that Polaris helped scale from an early-stage venture [1]. The firm also guided Ironwood Pharmaceuticals from its early days as a seed-funded startup to its current status as a public, commercial-stage company [1]. With offices in Boston, New York, and San Francisco, Polaris leverages a broad network to connect founders with the capital and talent required to transform scientific discovery into life-changing medical outcomes [1][2].
RA Capital Management
RA Capital Management, founded in 2002 by Richard Aldrich and Peter Kolchinsky, is a Boston-based investment firm that focuses on the entire healthcare innovation lifecycle [1][2]. Managing over $14 billion in assets, the firm is distinguished by its 'evidence-based' investing model, which is powered by its TechAtlas research engine—a team of over 200 professionals, many with MDs and PhDs, who map disease and technology landscapes [1][3]. This deep market intelligence allows RA Capital to identify and fund high-potential science from 'NewCo' origination and seed rounds through crossover financings and support in public markets [3]. RA Capital is known for its flexible capital solutions and its ability to act as a long-term partner for companies through clinical and commercial development [1]. Notable portfolio companies include Intellia Therapeutics, where the firm provided pivotal crossover financing to support the company's CRISPR-based platform, and Rubius Therapeutics, which it backed to develop cellular therapies [1]. By infusing companies with enough capital to pursue multiple programs in parallel, RA Capital helps its portfolio avoid the binary risks common in biotech and build enduring value for patients and investors alike [5].
What founders should keep in mind
Healthcare and biotech fundraises hinge on different diligence questions than a typical SaaS raise — investors will probe your IP position, regulatory strategy, and the credibility of your clinical or scientific plan well before they discuss valuation. Because milestones (IND filings, clinical readouts, FDA clearances) drive step-changes in company value, the structure of your term sheet and any liquidation preference stack matter even more than usual, since multiple future financing rounds are often required before commercial revenue appears.
Founders raising a first institutional round should also look closely at how convertible notes and SAFEs are used to bridge between scientific milestones, and should expect thorough due diligence on data integrity, lab notebooks, and regulatory filings. For companies targeting a Series A in therapeutics or medtech, understanding what investors look for at Series A is essential groundwork before approaching any of the firms above.
It is also worth understanding which of these investors prefer to co-found and incubate companies internally, such as Flagship Pioneering, Versant Ventures, and ARCH Venture Partners, versus those that primarily evaluate outside pitches from founding teams that have already assembled their own science and leadership, such as OrbiMed and RA Capital. Approaching a company-creation-oriented fund with a fully formed pitch deck, or approaching a traditional check-writer expecting them to help build your founding team from scratch, is a common mismatch that wastes time on both sides. Matching your stage of company formation to a firm's actual investment model is one of the simplest ways to shorten your fundraising timeline in this sector.
Closing thoughts
The firms above represent a cross-section of specialist and generalist healthcare investors actively deploying capital in 2026, but the right fit depends heavily on your stage, modality, and indication. Quantum Growth Advisors helps healthcare and biotech founders build the data room, narrative, and investor targeting strategy needed to run an efficient Series A process. If you're preparing a raise, book a free consult with our team to discuss your fundraising strategy.